Plain-English translation of NCT06972446 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Rheumatoid Arthritis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing three different new medications called and to treat moderate to severe rheumatoid arthritis in people whose condition has not responded well to previous biologic therapies. The study compares each medication (given alone or together) against a placebo (a dummy treatment with no active medicine) to see which works best and is safe to use. This research aims to give people with hard-to-treat arthritis new options when current treatments aren't working.
Rheumatoid arthritis causes lasting pain, stiffness, and joint damage, but not everyone responds well to treatments that currently exist. This trial is exploring whether these new targeted medications can help people whose condition has already failed to improve with one or two previous biologic treatments.
You likely qualify if…
You likely don't qualify if…
You will visit a hospital or clinic regularly throughout the study to receive either the new medication or a placebo injection, have blood tests done, and answer questions about your symptoms and how you're feeling. You'll be randomly assigned to one of the three medication studies, and within each study, you'll have a 50/50 chance of getting the active treatment or the placebo. The study involves more frequent visits than typical arthritis care, and researchers will carefully monitor you for any side effects and measure whether your arthritis improves.
AI-generated summary from trial data · Jul 13, 2026 · Not medical advice
United States